Telix Expands Prostate Cancer Activity with GenesisCare Collaboration MELBOURNE, Australia, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today releases details of two ancillary studies under the ProstACT program...

Telix Pharmaceuticals and GenesisCare Commence ENHANCING Prostate Cancer Clinical Study MELBOURNE, Australia and SYDNEY, Australia, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on...

GenesisCare and Telix Enter into Strategic Collaboration Agreement to Accelerate Patient Access to New Treatments MELBOURNE, Australia and SYDNEY, Australia, Oct. 10, 2018 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on...